Correction to: Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4) (Urolithiasis, (2023), 51, 1, (80), 10.1007/s00240-023-01453-3)

David S. Goldfarb; John C. Lieske; Jaap Groothoff; Gesa Schalk; Kerry Russell; Shuli Yu; Blaz Vrhnjak

doi:https://doi.org/10.1007/s00240-023-01455-1

Correction to: Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4) (Urolithiasis, (2023), 51, 1, (80), 10.1007/s00240-023-01453-3)

David S. Goldfarb, John C. Lieske, Jaap Groothoff, Gesa Schalk, Kerry Russell, Shuli Yu, Blaz Vrhnjak

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Abstract

The original version of this article unfortunately contained a mistake.

Original language	English
Article number	85
Pages (from-to)	85
Journal	Urolithiasis
Volume	51
Issue number	1
DOIs	https://doi.org/10.1007/s00240-023-01455-1
Publication status	Published - Dec 2023

Access to Document

https://doi.org/10.1007/s00240-023-01455-1

Cite this

@article{a35af52b95c8421b9161c9006dab4dd6,

title = "Correction to: Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4) (Urolithiasis, (2023), 51, 1, (80), 10.1007/s00240-023-01453-3)",

abstract = "The original version of this article unfortunately contained a mistake.",

author = "Goldfarb, {David S.} and Lieske, {John C.} and Jaap Groothoff and Gesa Schalk and Kerry Russell and Shuli Yu and Blaz Vrhnjak",

note = "Publisher Copyright: {\textcopyright} 2023, Springer-Verlag GmbH Germany, part of Springer Nature.",

year = "2023",

month = dec,

doi = "https://doi.org/10.1007/s00240-023-01455-1",

language = "English",

volume = "51",

pages = "85",

journal = "Urolithiasis",

issn = "2194-7228",

publisher = "Springer Verlag",

number = "1",

}

Correction to: Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4) (Urolithiasis, (2023), 51, 1, (80), 10.1007/s00240-023-01453-3). / Goldfarb, David S.; Lieske, John C.; Groothoff, Jaap et al.
In: Urolithiasis, Vol. 51, No. 1, 85, 12.2023, p. 85.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - Correction to

T2 - Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4) (Urolithiasis, (2023), 51, 1, (80), 10.1007/s00240-023-01453-3)

AU - Goldfarb, David S.

AU - Lieske, John C.

AU - Groothoff, Jaap

AU - Schalk, Gesa

AU - Russell, Kerry

AU - Yu, Shuli

AU - Vrhnjak, Blaz

PY - 2023/12

Y1 - 2023/12

N2 - The original version of this article unfortunately contained a mistake.

AB - The original version of this article unfortunately contained a mistake.

UR - http://www.scopus.com/inward/record.url?scp=85160979304&partnerID=8YFLogxK

U2 - https://doi.org/10.1007/s00240-023-01455-1

DO - https://doi.org/10.1007/s00240-023-01455-1

M3 - Comment/Letter to the editor

C2 - 37273015

SN - 2194-7228

VL - 51

SP - 85

JO - Urolithiasis

JF - Urolithiasis

IS - 1

M1 - 85

ER -

Correction to: Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4) (Urolithiasis, (2023), 51, 1, (80), 10.1007/s00240-023-01453-3)

Abstract

Access to Document

Other files and links

Cite this